|
|
Atricure Inc (NASDAQ: ATRC) |
|
Price: $48.3500
$-0.19 
-0.391%
|
| Day's High:
| $48.845001220703125
| Week Perf:
| -0.68 %
|
| Day's Low: |
$ 46.61 |
30 Day Perf: |
28.05 % |
| Volume (M): |
529,116 |
52 Wk High: |
$ 49.98 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$34.40 |
| Open: |
$48.13 |
52 Wk Low: |
$25.36 |
|
|
| Market Capitalization (Millions $) |
2,363 |
| Shares
Outstanding (Millions) |
49 |
| Employees |
1,350 |
| Revenues (TTM) (Millions $) |
568 |
| Net Income (TTM) (Millions $) |
11 |
| Cash Flow (TTM) (Millions $) |
28 |
| Capital Exp. (TTM) (Millions $) |
8 |
Business Description
Atricure Inc is a leading medical technology company that specializes in the development and commercialization of innovative devices that help surgeons around the world to perform better cardiac surgery procedures. The company's main focus is on the provision of advanced and minimally invasive surgical solutions that enhance patient outcomes and reduce healthcare costs.
Atricure was founded in 2000, and since then, it has become an industry leader in the field of electrophysiology, with a particular focus on the treatment of atrial fibrillation (AF). The company is headquartered in Mason, OH, and has a team of over 900 employees worldwide, including in Europe, Asia, and the Americas.
Atricure's product portfolio includes a range of advanced surgical devices and instruments that are used to treat various cardiac conditions. Some of the company's key products include the AtriCure CryoICE Cryoablation System, the AtriClip Left Atrial Appendage Management System, and the EPi-Sense Coagulation System.
The AtriCure CryoICE Cryoablation System is a minimally invasive system that delivers cold energy to the heart tissue to create a controlled lesion, which stops the abnormal electrical signals that can cause AF. The AtriClip Left Atrial Appendage Management System is designed to exclude the left atrial appendage from the circulation, reducing the risk of stroke in patients with AF.
The EPi-Sense Coagulation System is a bipolar radiofrequency energy device that helps surgeons safely create critically important lines of conduction block in the heart, which can help treat a range of cardiac abnormalities including AF.
Atricure is committed to innovation and product development, maintaining partnerships with leading researchers and medical institutions, and investing significant amounts in R&D every year. The company's culture is rooted in collaboration, integrity, passion, and excellence, and it places a significant emphasis on investing in employee development, diversity, and inclusion.
In conclusion, Atricure Inc is a leading medical technology company that has been at the forefront of innovation in the field of cardiac surgery. With a robust product portfolio, a strong commitment to R&D, and a culture of excellence, the company is well-positioned to achieve sustained growth and remain an industry leader in the years to come.
Company Address: 7555 Innovation Way Mason 45040 OH
Company Phone Number: 755-4100 Stock Exchange / Ticker: NASDAQ ATRC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Wed, Oct 29 2025 6:20 PM UTC
Innovative Strides and Financial Ambitions: AtriCure’s Path to Preeminence in Cardiovascular Therapies In a series of groundbreaking announcements, AtriCure, Inc. (Nasdaq: ATRC) is demonstrating a robust commitment to advancing cardiovascular health through innovative clinical trials, cutting-edge device implementation, and strategic financial aspirations. As the company ...
|
| Business Update
Published Mon, Jan 13 2025 4:29 PM UTC
In a revealing announcement, AtriCure, Inc. (NASDAQ: ATRC), a pioneering entity in surgical treatments for atrial fibrillation (Afib) and related health issues, disclosed its preliminary financial results for the fourth quarter and full year of 2024. As the company gears up for its upcoming Analyst & Investor Day scheduled for March 26, 2025, in Mason, Ohio, analysts are kee...
|
| Business Update
Published Wed, Nov 20 2024 2:39 PM UTC
In the ever-evolving landscape of medical technology, few companies are making as significant an impact as AtriCure, Inc. (Nasdaq: ATRC). Based in Mason, Ohio, this leading innovator specializes in surgical treatments and therapies aimed at addressing atrial fibrillation (Afib), a common and potentially dangerous heart rhythm disorder. With their recent developments and grow...
|
| Business Update
Published Tue, Oct 15 2024 1:36 PM UTC
In the ever-evolving landscape of medical technology, innovation has become the heartbeat of progress. This rings particularly true in the field of surgical procedures and post-operative care, where patient comfort and recovery are paramount. AtriCure, Inc. (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation and left atrial appendage management, is poised...
|
| Business Update
Published Wed, Oct 2 2024 12:47 AM UTC
AtriCure s Innovative Leap: Navigating Financial Challenges with European CE Certification MASON, Ohio In a remarkable stride forward, AtriCure, Inc. (Nasdaq: ATRC), a trailblazing innovator in the realm of surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and postoperative pain management, has announced a significant...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.21 $ |
| Revenues (TTM) |
11.62 $
|
| Cash Flow (TTM) |
0.58 $ |
| Cash |
3.43 $
|
| Book Value |
10.57 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
420,553 |
| Net
Income per Employee (TTM) |
7,816 |
| Receivable Turnover Ratio (TTM) |
8.08 |
| Inventory Turnover Ratio (TTM) |
1.67 |
| Asset Turnover Ratio (TTM) |
0.87 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.21 $
|
| Revenues (TTM) |
11.62 $ |
| Cash Flow (TTM) |
0.58 $ |
| Cash |
3.43 $
|
| Book Value |
10.57 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Openheart |
|
 13.51 % |
of total Revenue |
| Minimally Invasive |
|
2.56 % |
of total Revenue |
| Pain Management |
|
2.84 % |
of total Revenue |
| Appendage Management |
|
15.62 % |
of total Revenue |
| United States |
|
157.41 % |
of total Revenue |
| Non-US |
|
34.54 % |
of total Revenue |
| Europe |
|
10.23 % |
of total Revenue |
| Other International |
|
2.65 % |
of total Revenue |
| |
On January 13 2025 the Atricure Inc provided following guidance
### AtriCure Inc. Announces Preliminary Fourth Quarter and Full Year 2024 Results, Provides Financial Projections for 2025, and Schedules Analyst and Investor Day
MASON, Ohio—AtriCure, Inc. (Nasdaq: ATRC), a prominent leader in the development of innovative surgical solutions and therapies addressing atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain control, has released its preliminary financial results for both the fourth quarter and the entire year of 2024. Alongside this, the company has also outlined its financial expectations for 2025.
While specific figures regarding the 2025 financial outlook have not been disclosed, AtriCure remains commi...
|
|
|
2.28% 